SCHEMBL2782013

SCHEMBL2782013

c1ccc2c(N3CCCC3)c[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
KDM4E B2RXH2 3/20 0.51
HTT P42858 2/20 0.51
MAPK1 P28482 1/20 0.51
JAK2 O60674 1/20 0.50
RAB9A P51151 1/20 0.50
BCHE P06276 1/20 0.47
CYP2D6 P10635 1/20 0.47
POLB P06746 3/20 0.46
HTR2A P28223 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 4/20 0.45
HTR6 P50406 2/20 0.45
ADRB1 P08588 1/20 0.45
HTR1A P08908 2/20 0.44
ATM Q13315 1/20 0.44
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
DRD2 P14416 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1413377 0.98 HTT (0.54) LMNAKDM4EHTTMAPK1JAK2
Hydrochloric Acid SCHEMBL11852231 0.96 JAK2 (0.55) LMNAKDM4EHTTMAPK1JAK2
SCHEMBL6407264 0.92 LMNA (0.51) LMNAKDM4EHTTMAPK1BCHE
SCHEMBL16801682 0.87 HTR6 (0.56) LMNAKDM4ECYP2D6HTR2AHTR6
SCHEMBL1442314 0.85 HTR6 (0.63) LMNAKDM4ECYP2D6HTR2AHTR6
SCHEMBL1413397 0.84 HTR6 (0.56) LMNAKDM4EHTTPOLBHTR2A
SCHEMBL7548171 0.84 BCHE (0.44) LMNAKDM4EHTTMAPK1JAK2
SCHEMBL1413396 0.84 ALDH1A1 (0.55) LMNAKDM4ECYP2D6KMT2AMAPT
SCHEMBL21047718 0.82 BCHE (0.42) LMNAKDM4EHTTJAK2RAB9A
SCHEMBL21047732 0.81 ALDH1A1 (0.41) LMNAKDM4EHTTMAPK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368470-B2 Substituted 3-pyrrolidine-indole derivatives GRUENENTHAL GMBH (DE) 2008-05-06 US claimed
EP-1654253-B1 SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-01-03 EP claimed
US-20050096376-A1 Substituted 3-pyrrolidine-indole derivatives GRUENENTHAL GMBH (DE) 2005-05-05 US claimed
CN-1047386-C Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1999-12-15 CN claimed
US-5763471-A TREATS PSYCHIATARIC AND BRAIN DISORDERS CEMAF (FR) 1998-06-09 US claimed
CN-1148855-A Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1997-04-30 CN claimed
CN-119930875-A Composite catalyst and preparation method of cycloolefin copolymer using same 金发科技股份有限公司 2025-05-06 CN disclosed
WO-2024026574-A1 3-PYRROLIDINE-INDOLE DIMERS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO MINDSET PHARMA INC. (CA) 2024-02-08 WO disclosed
US-20230105399-A1 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS MINDSET PHARMA INC. (CA) 2023-04-06 US disclosed
EP-4100403-A1 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS Mindset Pharma Inc. (CA) 2022-12-14 EP disclosed
CN-115380028-A 3-pyrrolidine-indole derivatives as serotonergic hallucinogens for the treatment of CNS disorders 明德赛特制药公司 2022-11-22 CN disclosed
CN-115380028-A 3-pyrrolidine-indole derivatives as serotonergic hallucinogens for the treatment of CNS disorders 明德赛特制药公司 2022-11-22 CN disclosed
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS Frequency Therapeutics, Inc. (US) 2022-05-05 US disclosed
US-20050096376-A1 Substituted 3-pyrrolidine-indole derivatives GRUENENTHAL GMBH (DE) 2005-05-05 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2005019208-A1 SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES Grünenthal GmbH (DE) 2005-03-03 WO disclosed
WO-2005019208-A1 SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES Grünenthal GmbH (DE) 2005-03-03 WO disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
CN-1047386-C Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1999-12-15 CN disclosed
CN-1148855-A Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1997-04-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 LMNA 4828/4885KDM4E 3859/4885HTT 4710/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 LMNA 4803/4885KDM4E 3850/4885HTT 4668/4885
US-20230105399-A1 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS HTR3A, TPH1, HTR5A LMNA 2030/4885KDM4E 3617/4885HTT 431/4885
US-20220133740-A1 VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS WNT3A, WNT1, WNT3 LMNA 1856/4885KDM4E 853/4885HTT 3254/4885
US-20050096376-A1 Substituted 3-pyrrolidine-indole derivatives OPRD1, OPRK1, TPH1 LMNA 3265/4885KDM4E 1917/4885HTT 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.